Mercury Laboratories Ltd (538964) — FY26 Annual Report | 1 September 2026

Mercury Laboratories Ltd's FY 2025-26 Annual Report shows revenue of ₹7,593.67 Lakhs and net profit of ₹483.39 Lakhs, up 53.71% YoY, with a recommended dividend of [amount context mismatch] per share. The 45th AGM is scheduled for September 28, 2026, via video conference, with e-voting from September 24-27. Key governance updates include re-appointment of directors, approval of remuneration for Non-Executive Director Ms. Janki R Shah (₹62 Lakhs/year) and COO Mr. Saurabh Mittal (₹86 Lakhs/year cap), and ratification of cost auditor remuneration. The company maintains strong governance compliance, with no material related-party transactions, no fraud reported, and unmodified audit opinion. Employee remuneration increased 5.70% for non-managerial staff. Shareholding stands at 73.66% promoter-owned, with 1,600 shares transferred to IEPF for FY 2017-18. The report highlights export growth of 18.62% and strategic focus on Gynecology and Pediatrics segments.